

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-450-A)

In re Application of:

Polverino et al.)	
)	
Serial No.: 09/724,000)	Examiner: S. Rawlings
)	
Filed: November 28, 2000)	Group Art Unit: 1643
)	
For: Secreted Epithelial Colon Stromal-1)	Confirmation No: 6633
Molecules and Uses Thereof)	

SUPPLEMENTAL DECLARATION PURSUANT TO 37 C.F.R. § 1.131

We, Anthony J. Polverino, residing at 10871 Bill Point Circle NE, Bainbridge Island, Washington, and Roland Luethy, residing at 7300 Worth Way, Camarillo, California, hereby declare:


1. We are named co-inventors on United States Patent Application No. 09/724,000, filed on November 28, 2000.
2. United States Patent Application No. 09/724,000 is a continuation-in-part of United States Patent Application No. 09/599,087 filed on June 21, 2000.
3. This Supplemental Declaration incorporates the Declaration Pursuant to 37 C.F.R. § 1.131 executed on July 22, 2002 and filed on July 23, 2002; the Declaration Pursuant to 37 C.F.R. § 1.131 executed on September 25, 2002 and filed on October 23, 2002; and the Declaration Pursuant to 37 C.F.R. § 1.131 executed on March 27, 2007 and March 28, 2007 and filed on March 29, 2007; all of which were submitted with respect to the instant application.
4. At a date prior to September 24, 1999, we recognized that the open reading frame of the nucleotide sequence set forth in SEQ ID NO: 4, initiating with the first codon encoding methionine (i.e., the sequence ATG at positions 29-31 of that sequence), encodes a polypeptide having the amino acid sequence set forth in the instant application as SEQ ID NO: 5.
5. At a date prior to September 24, 1999, we determined that the putative

signal peptide of Secs-1 consisted of residues 1-24 of the amino acid sequence set forth in SEQ ID NO: 5, thus establishing the mature form of the polypeptide set forth in SEQ ID NO: 6.

6. After isolating the secreted protein, we would have easily identified the amino-terminal residue of the mature form of the polypeptide set forth in SEQ ID NO: 6.

7. We hereby declare further that all statements made herein by each of us to our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: 7/26/07

Signed: 
Anthony J. Polverino

Dated: _____

Signed: _____
Roland Luethy

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-450-A)

In re Application of:

Polverino et al.)		
)		
Serial No.: 09/724,000)	Examiner:	S.
Rawlings)		
)		
Filed: November 28, 2000)	Group Art Unit:	1643
)		
For: Secreted Epithelial Colon Stromal-1)	Confirmation	
No: 6633)		
Molecules and Uses Thereof)		

SUPPLEMENTAL DECLARATION PURSUANT TO 37 C.F.R. §
1.131

We, Anthony J. Polverino, residing at 10871 Bill Point Circle NE, Bainbridge Island, Washington, and Roland Luethy, residing at 7300 Worth Way, Camarillo, California, hereby declare:

1. We are named co-inventors on United States Patent Application No. 09/724,000, filed on November 28, 2000.
2. United States Patent Application No. 09/724,000 is a continuation-in-part of United States Patent Application No. 09/599,087 filed on June 21, 2000.
3. This Supplemental Declaration incorporates the Declaration Pursuant to 37 C.F.R. § 1.131 executed on July 22, 2002 and filed on July 23, 2002; the Declaration Pursuant to 37 C.F.R. § 1.131 executed on September 25, 2002 and filed on October 23, 2002; and the Declaration Pursuant to 37 C.F.R. § 1.131 executed on March 27, 2007 and March 28, 2007 and filed on March 29, 2007; all of which were submitted with respect to the instant application.
4. At a date prior to September 24, 1999, we recognized that

the open reading frame of the nucleotide sequence set forth in SEQ ID NO: 4, initiating with the first codon encoding methionine (i.e., the sequence ATG at positions 29-31 of that sequence), encodes a polypeptide having the amino acid sequence set forth in the instant application as SEQ ID NO: 5.

5. At a date prior to September 24, 1999, we determined that the putative signal peptide of Secs-1 consisted of residues 1-24 of the amino acid sequence set forth in SEQ ID NO: 5, thus establishing the mature form of the polypeptide set forth in SEQ ID NO: 6.

6. After isolating the secreted protein, we would have easily identified the amino-terminal residue of the mature form of the polypeptide set forth in SEQ ID NO: 6.

7. We hereby declare further that all statements made herein by each of us to our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: _____

Signed: _____
Anthony J. Polverino

Dated: 7/27/07

Signed: 
Roland Luethy